Publications by authors named "A S Popa"

Objective: this retrospective study aimed to evaluate the impact of BRCA mutational status on the outcomes of patients with advanced ovarian cancer treated with either primary debulking surgery (PDS) or neoadjuvant chemotherapy followed by interval debulking surgery (NACT-IDS). Material and a total of 79 patients with stage III-IV ovarian cancer treated at Elias Emergency University Hospital between January 2014 and March 2024 were included. Patients received either PDS followed by chemotherapy or NACT-IDS.

View Article and Find Full Text PDF

: LL-37 is associated with metabolic syndrome (MetS), a constellation of risk factors comprising obesity, insulin resistance (IR), dyslipidemia, and hypertension, which elevates the risk of cardiovascular disease and type 2 diabetes. : In this narrative review, we analyzed the literature focusing on recent developments in the relationship between cathelicidin and various components of MetS to provide a comprehensive overview. : Studies have shown that LL-37 is linked to inflammation in adipose tissue (AT) and the development of IR in obesity.

View Article and Find Full Text PDF

Colorectal cancer (CRC) remains a significant global health burden, necessitating a thorough understanding of prognostic and predictive factors to enhance patient outcomes. This systematic review aims to comprehensively evaluate prognostic and predictive determinants in CRC, encompassing both traditional and emerging biomarkers. A systematic search of major electronic databases was conducted to identify relevant studies published from 1995 up to 2024.

View Article and Find Full Text PDF

Over the past two decades, the CICECO-hub scientists have devoted substantial efforts to advancing bioactive inorganic materials based on calcium phosphates and alkali-free bioactive glasses. A key focus has been the deliberate incorporation of therapeutic ions like Mg, Sr, Zn, Mn, or Ga to enhance osteointegration and vascularization, confer antioxidant properties, and impart antimicrobial effects, marking significant contributions to the field of biomaterials and bone tissue engineering. Such an approach is expected to circumvent the uncertainties posed by methods relying on growth factors, such as bone morphogenetic proteins, parathyroid hormone, and platelet-rich plasma, along with their associated high costs and potential adverse side effects.

View Article and Find Full Text PDF
Article Synopsis
  • Exploiting TRAILR2 activation could improve cancer treatments, but past therapies faced issues like low effectiveness and liver damage.
  • The new TR2/CDH3 BAB antibody targets both CDH3 and TRAILR2, enhancing apoptosis specifically in tumor cells expressing CDH3, showcasing effectiveness in various cancers and CRISPR-engineered models.
  • In pancreatic cancer, where current treatments are lacking, TR2/CDH3 BAB shows promise, especially when used with other chemotherapy drugs, indicating potential for effective cancer therapy with a good safety profile.
View Article and Find Full Text PDF